Strategic financing will enable MolecuLight to further accelerate commercialization PITTSBURGH , Jan. 6, 2025 /PRNewswire/ -- MolecuLight Inc. , a global medical device company pioneering point-of-care fluorescence imaging for measuring bacterial load in wounds, today announced it has secured a $27.
5 million investment from Hayfin Capital Management LLP ("Hayfin"). This significant investment will accelerate MolecuLight's continued growth in the United States , Canada , and Europe across hospital in-patient and out-patient clinics, independent wound care clinics, podiatrists, mobile care, skilled nursing facilities, and long-term care centers. MolecuLight's innovative fluorescence imaging devices are transforming the way healthcare providers detect and treat infections.
By providing real-time visualization of harmful bacteria in all wound types, these devices empower clinicians to make informed decisions and improve patient outcomes while reducing cost-to-care 1,2 . This includes shortened healing times, reduced use of unnecessary antibiotics, complication avoidance, and minimized failure of skin substitutes products 1,3,4 ..
"We are thrilled to partner with Hayfin, a leading global alternative investment manager which has extensive investment experience in companies focused on wound care," said Anil Amlani, CEO of MolecuLight. "This investment will enable us to accelerate our goal of improving how wounds are treated worldwide. We will further expand our footprint to reach mo.